About Pathwork Diagnostics
Pathwork Diagnostics, Inc. develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.
Company timeline:
| 2003 |
Pathwork Informatics, Inc., begins development of microarray technology for genomic analysis of tumor tissues. |
| 2006 |
Predicant Biosciences, Inc., acquires the company; the new organization is renamed Pathwork Diagnostics, Inc. |
| 2008 |
Pathwork Diagnostics offers its first commercial product, the Tissue of Origin Test for frozen specimens, through its CLIA-certified laboratory.
The Tissue of Origin Test for frozen specimens is cleared by the FDA as an in vitro diagnostic (IVD) kit.
|
| 2009 |
Pathwork Diagnostics offers its second commercial product, the Tissue of Origin Test for formalin-fixed, paraffin-embedded specimens, through its CLIA-certified laboratory. |
Learn about the Pathwork management team.
Learn about our investment partners.
Learn about the Tissue of Origin Test.
Visit the Newsroom.